Recent Updates
Recently added Catalysts
ALGS Positive Sentiment

Bridget Martell

Key Takeaway: Bridget Martell, M.A., M.D., has been a board member since November 2021. She previously served as CEO of Artizan Biosciences and has held various leadership roles in multiple biopharmaceutical companies. Dr. Martell has a robust educational background, including a B.S. in microbiology and an M.D. from the Chicago Medical School.
Price reaction · baseline $12.325 (2024-08-14 close) · hit after-hours · 3 other ALGS headline(s) in the window, move may be shared
day 0 close
-2.6%
day 1
+6.5%
day 3 · peak
+17.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Dr. Martell has extensive leadership experience in biopharma.
  • She has held significant roles in multiple public biopharmaceutical companies.
  • Her educational background is strong, with degrees from reputable institutions.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+153%
120-day peak, hindsight
Typical move
6.1%
average across 6 past catalysts
Cash runway
~3 mo
High dilution risk
Lead asset
ALG-055009
Phase 2 · NASH

Full Press Release Details

Bridget Martell, M.A., M.D. has served as a member of our board of directors since November 2021. Dr. Martell has also served as President and Chief Executive Officer of Artizan Biosciences, Inc., a biotechnology company from July 2021-August 2023, a part-time Healthcare Venture Partner with AlleyCorp, an early stage venture capital company, from June 2021-May 2023, and an independent board director of Achieve Life Sciences, since March 2020, POINT Biopharma (now a wholly owned subsidiary of Lilly, Inc.), from June 2023-December 2023, and Ayala Pharmaceuticals, since October 2023, all public biopharmaceutical companies. Under the auspice of her consulting practice, BAM Consultants LLC, Dr. Martell has held various leadership positions in early stage, private companies, including Chief Medical Officer of Nobias Therapeutics from August 2020 to August 2021, Verseau Therapeutics from October 2020 to September 2021, and RRD International, a boutique Contract Research Organization, from April 2018 to January 2020. Concurrently, Dr. Martell held various full and part-time positions at Kura Oncology, a clinical-stage biopharmaceutical company, including VP, Clinical Development from October 2017 to January 2020, as Acting Chief Medical Officer from January 2020 to August 2020 and as Senior Scientific Advisor from August 2020 to December 2021. From January 2015 to September 2017, Dr. Martell served as Senior Vice President, New Product Development at Juniper Pharmaceuticals, a publicly-held specialty pharmaceuticals company. From October 2011 to April 2013, she was Executive Director, Head Medical Affairs at Purdue Pharma L.P., a privately-held pharmaceutical company. Prior to that, Dr. Martell held leadership roles of increasing responsibility at Pfizer, Inc., a publicly traded biopharmaceutical company, from 2005 to 2011. Dr. Martell received her B.S. in microbiology from Cornell University, her M.A. in molecular immunology from Boston University and her M.D. from the Chicago Medical School. She completed her internship and residency in internal medicine and was an internal medicine chief resident and RWJ Faculty Clinical Scholar at Yale University. Dr. Martell is board certified in both internal and addiction medicine.

Frequently Asked Questions

What positions has Bridget Martell held?

Bridget Martell has served as CEO of Artizan Biosciences and held various roles in other biopharma companies.

What is Dr. Martell's educational background?

Dr. Martell has a B.S. in microbiology, an M.A. in molecular immunology, and an M.D.

When did Dr. Martell join the ALGS board?

She has been a member of the ALGS board since November 2021.

What is BAM Consultants LLC?

BAM Consultants LLC is Dr. Martell's consulting practice, where she provides leadership in biopharma.

Last updated: Aug 14, 2024